ARTICLE | Clinical News
Pharmos, Bausch & Lomb Pharmaceuticals Inc. regulatory update
April 15, 2013 7:00 AM UTC
The FDA issued an approvable letter for the companies' NDA for PARS Lotemax (loteprodnol etabonate), an anti-inflammatory topical steroid, contingent on resolving labeling and certain technical issue...